Stockscreener 앱 받기
13.01
2.25%
-0.30
시간 외 거래:
13.07
0.06
+0.46%
전일 마감가:
$13.31
열려 있는:
$13.51
하루 거래량:
1.52M
Relative Volume:
1.47
시가총액:
$1.34B
수익:
-
순이익/손실:
$-167.48M
주가수익비율:
-5.6565
EPS:
-2.3
순현금흐름:
$-197.47M
1주 성능:
-17.97%
1개월 성능:
-13.32%
6개월 성능:
-19.54%
1년 성능:
+7.17%
1일 변동 폭
$12.86
$13.76
1주일 범위
$12.86
$15.91
52주 변동 폭
$11.30
$18.07
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
명칭
Day One Biopharmaceuticals Inc
전화
650 484-0899
주소
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
DAWN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| DAWN | 13.01 | 1.34B | 0 | -167.48M | -197.47M | -2.30 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-09 | 재확인 | Needham | Buy |
| 2024-08-01 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2024-04-24 | 재확인 | Needham | Buy |
| 2023-04-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-02-08 | 개시 | CapitalOne | Overweight |
| 2023-02-03 | 개시 | Oppenheimer | Perform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-12-05 | 개시 | Goldman | Buy |
| 2022-12-01 | 개시 | BofA Securities | Buy |
모두보기
Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스
Short Interest in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Rises By 12.8% - MarketBeat
First Week of July 2025 Options Trading For Day One Biopharmaceuticals (DAWN) - Nasdaq
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Day One Biopharmaceuticals to Present at Piper Sandler Healthcare Conference | DAWN Stock News - StockTitan
59,259 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by GSA Capital Partners LLP - MarketBeat
(DAWN) Trading Advice - Stock Traders Daily
TimesSquare Capital Management LLC Has $25.46 Million Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $180,257.35 in Stock - MarketBeat
FMR LLC Bolsters Position in Day One Biopharmaceuticals Inc - GuruFocus.com
Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? - Yahoo Finance
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Day One Biopharmaceuticals (NASDAQ:DAWN) Upgraded at TD Cowen - MarketBeat
Day one biopharmaceuticals head of R&D sells $8,010 in stock By Investing.com - Investing.com Canada
Day one biopharmaceuticals head of R&D sells $8,010 in stock - Investing.com
Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically - Simply Wall St
Bullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Forecasts - Yahoo Finance
Equities Analysts Issue Forecasts for DAWN Q1 Earnings - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth - Yahoo Finance
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2024 Earnings Call Transcript - Insider Monkey
Day One Biopharmaceuticals’ Revenue at Risk: Heavy Dependence on Few Key Customers - TipRanks
(DAWN) Proactive Strategies - Stock Traders Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Earnings Results, Beats Estimates By $0.58 EPS - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - MarketBeat
Pre-Market Trading Boosts Day One (DAWN) Amid High OJEMDA Demand - Stocks Telegraph
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Buy" Rating at HC Wainwright - MarketBeat
ChromaDex Q3 2024 Earnings Preview - MSN
Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates - MSN
Day One Biopharmaceuticals Reports Strong Q3 Growth - TipRanks
Day One Biopharmaceuticals earnings beat by $0.99, revenue topped estimates - Investing.com UK
DAWNDay One Biopharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress - The Manila Times
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap UpStill a Buy? - MarketBeat
Day One Biopharma shares retain overweight rating on ojemda drug usage - Investing.com UK
Day One Biopharmaceuticals (DAWN) to Release Earnings on Wednesday - MarketBeat
Global Cancer Antibody Drug Conjugates Market Size Forecast 2030 - GlobeNewswire Inc.
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet - Yahoo Finance
Research Analysts Set Expectations for DAWN Q3 Earnings - MarketBeat
How To Trade (DAWN) - Stock Traders Daily
Did Day One Biopharmaceuticals Inc (DAWN) perform well in the last session? - US Post News
Low Grade Glioma Market to Rise by 2034 | Day One - openPR
Day One Biopharmaceuticals (DAWN): Advancing Targeted Therapies for Pediatric Glioma - Insider Monkey
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024 - GlobeNewswire
Day One Biopharmaceuticals Breaks Above 200-Day Moving AverageBullish for DAWN - Nasdaq
Day One Biopharmaceuticals Inc (DAWN) is looking forward to a strong quarter - SETE News
Recent Insider Activity Suggests Potential Gains for Day One Biopharmaceuticals Inc (DAWN) - Knox Daily
184,230 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Purchased by Essex Investment Management Co. LLC - MarketBeat
The Significance of Moving Averages in Day One Biopharmaceuticals Inc Inc. (DAWN) Price Performance - The InvestChronicle
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Holdings Lifted by AQR Capital Management LLC - MarketBeat
Day One Biopharmaceuticals Inc [DAWN] Records 200-Day SMA of $14.60 - Knox Daily
Day One Biopharmaceuticals Inc (DAWN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):